TABLE 2.
Univariate proportional hazards analysis of ACE genotype and haplotype with renal outcomes
| Grades of diabetic nephropathy
|
|||||||
|---|---|---|---|---|---|---|---|
| ACE genotype
|
Persistent microalbuminuria (n = 246)
|
Severe nephropathy (n = 115)
|
|||||
| Single locus | Genotype comparisons | HR | 95% CI | Wald P value | HR | 95% CI | Wald P value |
| rs1800764 | CC vs. CT | 0.94 | 0.68–1.32 | 0.74 | 0.67 | 0.39–1.15 | 0.15 |
| TT vs. CT | 0.64 | 0.47–0.88 | 0.006* | 0.70 | 0.45–1.10 | 0.12 | |
| Insertion/deletion | DD vs. DI | 1.02 | 0.76–1.37 | 0.87 | 0.96 | 0.62–1.48 | 0.86 |
| II vs. DI | 0.67 | 0.47–0.95 | 0.026* | 0.69 | 0.41–1.15 | 0.15 | |
| rs9896208 | TT vs. CT | 1.09 | 0.76–1.56 | 0.63 | 0.96 | 0.57–1.61 | 0.88 |
| CC vs. CT | 0.70 | 0.53–0.93 | 0.015* | 0.60 | 0.39–0.92 | 0.020* | |
| Haplotype rs1800764, insertion/deletion, rs9896208 | |||||||
| CDT/CDT | 0.94 | 0.60–1.48 | 0.78 | 0.90 | 0.47–1.73 | 0.75 | |
| TIC/TIC | 0.56 | 0.37–0.85 | 0.007* | 0.53 | 0.29–0.97 | 0.04* | |
| CDC/CDT | 0.83 | 0.47–1.45 | 0.51 | 0.56 | 0.22–1.43 | 0.22 | |
| CDC/TIC | 0.78 | 0.51–1.19 | 0.25 | 0.69 | 0.36–1.33 | 0.27 | |
| CDT/other | 1.06 | 0.69–1.62 | 0.79 | 1.04 | 0.57–1.88 | 0.90 | |
| TIC/other | 0.66 | 0.42–1.06 | 0.09 | 0.77 | 0.40–1.49 | 0.44 | |
| Other/other | 0.71 | 0.34–1.49 | 0.36 | 0.54 | 0.16–1.76 | 0.30 | |
Each model was adjusted for study design (treatment, cohort, cohort by treatment interaction, and stratified by year of entry into DCCT). Indicated haplotypes are compared with the most frequent haplotype pair (CDT/TIC).
P < 0.05.